Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging
- PMID: 19154893
- DOI: 10.1016/j.jtcvs.2008.09.045
Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging
Abstract
Objective: There is an increase in interest in limited resection for clinical stage IA non-small cell lung cancer. The purpose of this study was to evaluate the accuracy of the diagnosis of clinical stage IA non-small cell lung cancer when determined by both computed tomography and positron emission tomography scans and to determine factors associated with understaging.
Methods: A retrospective review of a prospectively maintained database of patients with non-small cell lung cancer was performed. Patients with clinical stage IA cancer determined by preoperative computed tomography and positron emission tomography scan were reviewed. The influence of the following factors was analyzed with regard to accuracy of clinical staging: tumor size, location, histology, and positron emission tomography positivity.
Results: Of the 266 patients identified, cancer was correctly staged in 65%. Final pathologic stages also included IB (15%), IIA (2.6%), IIB (4.1%), IIIA (4.9%), IIIB (7.5%), and IV (.08%). Positive lymph nodes were found in 11.7% of patients. Pathologic T classification changed in 28.2% of patients. Cancer in patients with clinical tumor size greater than 2 cm (n = 68) was significantly more likely to be understaged than in patients with tumors 2 cm or less (49% vs 29%, P = .003). Cancer in patients with a positron emission tomography-positive (positron emission tomography +VE) primary evaluation (n = 218) was also more likely to be understaged (39% vs 15%, P = .001). Of patients with positron emission tomography +VE tumors greater than 2 cm, cancer was clinically understaged in 55%, compared with 32% for positron emission tomography +VE tumors 2 cm or less, and only 17% for positron emission tomography negative (-VE) tumors less than 2 cm.
Conclusion: Clinical stage IA lung cancer is frequently understaged in patients. Size greater than 2 cm and positron emission tomography positivity are risk factors for understaging. Limited resection should be undertaken with caution in such patients.
Comment in
-
Counterpoint: Despite staging inaccuracies, patients with non-small cell lung cancer are best served by having integrated positron emission tomography/computed tomography before therapy.J Thorac Cardiovasc Surg. 2009 Jan;137(1):20-2. doi: 10.1016/j.jtcvs.2008.08.048. J Thorac Cardiovasc Surg. 2009. PMID: 19154894 No abstract available.
Similar articles
-
The clinical stage of non-small cell lung cancer as assessed by means of fluorodeoxyglucose-positron emission tomographic/computed tomographic scanning is less accurate in cigarette smokers.J Thorac Cardiovasc Surg. 2006 Dec;132(6):1363-8. doi: 10.1016/j.jtcvs.2006.07.032. Epub 2006 Nov 20. J Thorac Cardiovasc Surg. 2006. PMID: 17140957
-
Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less.J Thorac Cardiovasc Surg. 2005 Dec;130(6):1611-5. doi: 10.1016/j.jtcvs.2005.07.014. J Thorac Cardiovasc Surg. 2005. PMID: 16308006
-
Limited resection for clinical Stage IA non-small-cell lung cancers based on a standardized-uptake value index.Eur J Cardiothorac Surg. 2013 Jan;43(1):e7-e12. doi: 10.1093/ejcts/ezs573. Epub 2012 Nov 4. Eur J Cardiothorac Surg. 2013. PMID: 23129358
-
Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.Eur J Cardiothorac Surg. 2009 Sep;36(3):440-5. doi: 10.1016/j.ejcts.2009.04.003. Epub 2009 May 22. Eur J Cardiothorac Surg. 2009. PMID: 19464906 Review.
-
Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases.Eur J Cardiothorac Surg. 2008 Oct;34(4):892-7. doi: 10.1016/j.ejcts.2008.07.023. Epub 2008 Aug 21. Eur J Cardiothorac Surg. 2008. PMID: 18722132 Review.
Cited by
-
The Impact of Preoperative Invasive Nodal Staging on Unexpected Mediastinal Upstaging in Early-Stage Non-small Cell Lung Cancer.Ann Surg Oncol. 2025 Jun;32(6):4151-4160. doi: 10.1245/s10434-025-17034-0. Epub 2025 Feb 20. Ann Surg Oncol. 2025. PMID: 39979686 Free PMC article.
-
The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer: An Analysis Based on Individual Participant Data.Chest. 2019 Mar;155(3):502-509. doi: 10.1016/j.chest.2018.10.020. Epub 2018 Oct 26. Chest. 2019. PMID: 30391190 Free PMC article.
-
Outcomes of Patients Undergoing Segmentectomy for Occult Node-Positive Clinical Stage IA Lung Cancer.Ann Thorac Surg. 2024 Sep;118(3):655-663. doi: 10.1016/j.athoracsur.2024.05.031. Epub 2024 Jun 10. Ann Thorac Surg. 2024. PMID: 38866198 Free PMC article.
-
Comparative Effectiveness of Lobectomy, Segmentectomy, and Wedge Resection for Pathological Stage I Non-small Cell Lung Cancer in Elderly Patients: A Population-Based Study.Front Surg. 2021 Apr 15;8:652770. doi: 10.3389/fsurg.2021.652770. eCollection 2021. Front Surg. 2021. PMID: 33937317 Free PMC article.
-
A pilot study of 4'-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer.EJNMMI Res. 2014 Mar 5;4(1):10. doi: 10.1186/2191-219X-4-10. EJNMMI Res. 2014. PMID: 24593883 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical